Exelixis, Inc. vs TG Therapeutics, Inc.: Annual Revenue Growth Compared

A Tale of Two Biotechs: Revenue Growth from 2014 to 2023

In the dynamic world of biotechnology, revenue growth is a key indicator of a company's success and potential. Over the past decade, Exelixis, Inc. and TG Therapeutics, Inc. have showcased contrasting trajectories in their annual revenues.

Exelixis, Inc. has experienced a remarkable surge, with its revenue growing from approximately $25 million in 2014 to an impressive $1.83 billion by 2023. This represents a staggering increase of over 7,200%, highlighting Exelixis's strategic advancements and market penetration.

Conversely, TG Therapeutics, Inc. has faced a more challenging path. Starting with a modest revenue of around $152,000 in 2014, the company saw minimal growth until 2021. However, a significant leap occurred in 2023, with revenues reaching approximately $234 million, marking a pivotal moment in its financial journey.

These trends underscore the diverse challenges and opportunities within the biotech sector, offering valuable insights for investors and industry enthusiasts alike.